Showing 8561-8570 of 21414 results for "".
New Developments in Incretins and SGLT Inhibitors
https://reachmd.com/programs/diabetes-discourse/new-developments-in-incretins-and-sglt-inhibitors/4694/The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major abnormalities that contribute to type 2 diabetes: impaired insulin secretion and excessive glucagon secretion. GLP-1 also appears to have effects on gastSurvodutide in Obesity: Insights from SYNCHRONIZE-1
https://reachmd.com/programs/clinicians-roundtable/survodutide-obesity-synchronize-1/57029/New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the eTRIUMPH-2: Translating New Obesity Data Into Real-World Care
https://reachmd.com/clinical-practice/endocrinology/triumph-2-translating-new-obesity-data-into-real-world-care/84844/Explore the TRIUMPH-2 findings and what emerging retatrutide data could mean for individualized obesity care in patients with type 2 diabetes.Use of Glucagon and Insulin in a Closed-Loop System
https://reachmd.com/programs/diabetes-discourse/use-of-glucagon-and-insulin-in-a-closed-loop-system/6259/The latest research into the use of glucagon and insulin in a closed-loop system is promising for the management of type 1 diabetes. How will the use of a bihormonal system benefit patients, and what is the path of treatment? Join host Dr. Steven Edelman and his guests, associate professor of biomedUsing Video Games to Improve Children’s Diets
https://reachmd.com/programs/diabetes-discourse/using-video-games-to-improve-childrens-diets/6294/How are video games showing promise as a behavior change strategy to improve children's diets? Newly-funded video-game programs are specifically designed to lower risk of type 2 diabetes and obesity in children. Join host Dr. Steven Edelman and his guest, professor of pediatrics at Baylor College,What is the Relationship Between Insulin Sensitivity and Puberty?
https://reachmd.com/programs/diabetes-discourse/what-is-the-relationship-between-insulin-sensitivity-and-puberty/5755/The emergence of type 2 diabetes in both children and adolescents suggests a relationship between insulin sensitivity and puberty. What are we learning from recent studies and clinical research? Join host Dr. Steven Edelman and his guest, professor of pediatrics at the University of Colorado, Dr. PhEmerging Insulin Pump Technology
https://reachmd.com/programs/diabetes-discourse/emerging-insulin-pump-technology/5108/Will insulin pumps become the preferred therapy for patients with type 2 diabetes who are not at goal? New insulin pump technology and patch pumps are offering a whole new level of customization, an ability to improve glucose control and quality of life. Join host Dr. Steven Edelman and his guest, ePart 1: A Plant-Based Diet for Preventing and Possibly Reversing Coronary Artery Disease
https://reachmd.com/programs/heart-matters/part-1-a-plant-based-diet-for-preventing-and-possibly-reversing-coronary-artery-disease/6249/Beta blockers, anticoagulants, stenting procedures and bypass surgeries: these are all crucial cornerstones of cardiology that have saved and improved the quality of lives for our patients, yet the underlying causes of coronary artery disease aren't addressed by interventions and medications. Can we"I think we're the bridge between the healthcare systems, the pharma systems, and the molecular diagnostic systems," says Matt Newman with Manifold
https://reachmd.com/programs/the-convergence/data-barriers-ai-smarter-faster-care/39923/From streamlining research to informing real-time decisions, AI-powered platforms are beginning to reshape how clinicians and researchers access and apply data in patient care. Learn more as Dr. Brian McDonough speaks with Matt Newman, Senior Vice President of Industry Solutions at Manifold, about hVNS Therapy Achieves Cost Neutrality Within 2 Years Across All US Payer Types
https://reachmd.com/programs/practical-neurology/vns-therapy-achieves-cost-neutrality-within-2-years-across-all-us-payer-types/49194/